Role of the Board
The Board is accountable to shareholders for ensuring that GSK is appropriately managed and achieves the strategic objectives it sets.
Sir Philip Hampton is the Chairman of our Board and Sir Andrew Witty is our Chief Executive Officer (CEO).
Emma Walmsley was appointed CEO designate on 20 September 2017 and will succeed Sir Andrew Witty when he retires 31 March 2017.
The role of the Chairman is to lead and manage the business of the Board to provide direction and focus, while ensuring that there is a clear structure for the effective operation of the Board and its Committees. He sets the agenda for Board discussions to promote effective and constructive debate and to support a sound decision-making process, ensuring that the Board receives accurate, timely and clear information, in particular about the company’s performance.
The Chairman and the Chairmen of Board committees communicate regularly with the CEO and other CET members. The division of responsibilities between the role of Chairman and the CEO has been set out in writing, agreed by the Board.